{"organizations": [], "uuid": "0b4f921ec5b6e9fcaabb940eb4ab511207a124fc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-alkermes-receives-refusal-to-file/brief-alkermes-receives-refusal-to-file-letter-from-fda-for-alks-5461-idUSFWN1RF062", "country": "US", "domain_rank": 408, "title": "BRIEF-Alkermes Receives Refusal To File Letter From FDA For ALKS 5461", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-02T14:05:00.000+03:00", "replies_count": 0, "uuid": "0b4f921ec5b6e9fcaabb940eb4ab511207a124fc"}, "author": "", "url": "https://www.reuters.com/article/brief-alkermes-receives-refusal-to-file/brief-alkermes-receives-refusal-to-file-letter-from-fda-for-alks-5461-idUSFWN1RF062", "ord_in_thread": 0, "title": "BRIEF-Alkermes Receives Refusal To File Letter From FDA For ALKS 5461", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "alkermes plc", "sentiment": "none"}, {"name": "alkermes plc", "sentiment": "none"}, {"name": "alkermes", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 2, 2018 / 11:05 AM / in 16 minutes BRIEF-Alkermes Receives Refusal To File Letter From FDA For ALKS 5461 Reuters Staff \nApril 2 (Reuters) - Alkermes Plc: \n* ALKERMES RECEIVES REFUSAL TO FILE LETTER FROM FDA FOR ALKS 5461 \n* ALKERMES PLC SAYS “STRONGLY DISAGREES WITH FDA’S CONCLUSIONS AND PLANS TO APPEAL FDA’S DECISION” \n* UPON ITS PRELIMINARY REVIEW, FDA HAS TAKEN POSITION THAT IT IS UNABLE TO COMPLETE A SUBSTANTIVE REVIEW OF REGULATORY PACKAGE \n* ‍FDA REQUESTED CONDUCT OF BIOAVAILABILITY STUDY TO GENERATE ADDITIONAL BRIDGING DATA BETWEEN ALKS 5461 & REFERENCE LISTED DRUG, BUPRENORPHINE​ \n* INTENDS TO SEEK IMMEDIATE GUIDANCE, INCLUDING REQUESTING A TYPE A MEETING WITH FDA TO DETERMINE NEXT STEPS REQUIRED TO RESUBMIT NDA \n* ISSUED FINANCIAL GUIDANCE FOR 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-02T14:05:00.000+03:00", "crawled": "2018-04-02T14:26:42.019+03:00", "highlightTitle": ""}